about
Impact of Telaprevir in HCV Patients with Cirrhosis and RVR: Real-Life Data from Boceprevir or Telaprevir based "Triple Therapy" Experience in Southern Italy.Indirect markers of non-alcoholic fatty liver disease: Another piece of the puzzle?The effect of antiviral therapy on hepatitis C virus-related thrombocytopenia: a case reportLiver biopsy in type 2 diabetes mellitus: Steatohepatitis represents the sole feature of liver damage.Insulin resistance and liver steatosis in chronic hepatitis C infection genotype 3.Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease.Helicobacter pylori infection but not small intestinal bacterial overgrowth may play a pathogenic role in rosacea.Management of the HBV reactivation in isolated HBcAb positive patients affected with Non Hodgkin Lymphoma.Rapid Virological Response Represents the Highest Prediction Factor of Response to Antiviral Treatment in HCV-Related Chronic Hepatitis: a Multicenter Retrospective Study."Non alcoholic fatty liver disease and eNOS dysfunction in humans"Clinical expression of insulin resistance in hepatitis C and B virus-related chronic hepatitis: differences and similarities.Antiviral therapy: why does it fail in HCV-related chronic hepatitis?Sustained virological response by direct antiviral agents in HCV leads to an early and significant improvement of liver fibrosis.Efficacy and safety of new direct antiviral agents in HCV infected patients with Diffuse Large B Cell Non-Hodgkin Lymphoma.Pharmacotherapy of alcoholic liver disease in clinical practice.A Long-term Treatment with Silybin in Patients with Non-alcoholic Steatohepatitis Stimulates Catalase Activity in Human Endothelial Cells.Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network.Occult hepatitis B virus infection in patients with non-Hodgkin lymphoma: the need for early diagnosis in anti-Hbc positive patients.Antiviral therapy after complete response to chemotherapy could be efficacious in HCV-positive non-Hodgkin's lymphoma.Steatohepatitis is associated with diabetes and fibrosis in genotype 1b HCV-related chronic liver disease.Qualitative and Quantitative Evaluation of Dietary Intake in Patients with Non-Alcoholic Steatohepatitis.Association between non-alcoholic fatty liver disease, insulin resistance and Helicobacter pylori.Interleukin-10 - 1082 GG polymorphism influences the occurrence and the clinical characteristics of hepatitis C virus infection.The impact of diet on liver fibrosis and on response to interferon therapy in patients with HCV-related chronic hepatitis.Correction to: "Non alcoholic fatty liver disease and eNOS dysfunction in humans".VIROLOGICAL PATTERNS OF HCV PATIENTS WITH FAILURE TO INTERFERON-FREE REGIMENS.Lactate determination in pleural and abdominal effusions: a quick diagnostic marker of exudate-a pilot study.Role of bisphenol A as environmental factor in the promotion of non-alcoholic fatty liver disease: in vitro and clinical study.Endocan Serum Levels in Patients with Non-Alcoholic Fatty Liver Disease with or without Type 2 Diabetes Mellitus: A Pilot Study.Lispro insulin in people with non-alcoholic liver cirrhosis and type 2 diabetes mellitus.The role of bright liver echo pattern on ultrasound B-mode examination in the diagnosis of liver steatosis.HCV-genotype 3h, a difficult-to-diagnose sub-genotype in the DAA era.Vascular Endothelial Dysfunction in Inflammatory Bowel Diseases: Pharmacological and Nonpharmacological Targets.Role of Oxidative Stress in Pathophysiology of Nonalcoholic Fatty Liver Disease.Erratum to: HBV and HCV infection in type 2 diabetes mellitus: a survey in three diabetes units in different Italian areasLung ultrasound for diagnosis of pneumonia in emergency departmentPressure support ventilation vs Continuous positive airway pressure for treating of acute cardiogenic pulmonary edema: A pilot studyChitosan-coated liposomes loaded with butyric acid demonstrate anticancer and anti-inflammatory activity in human hepatoma HepG2 cellsEvaluation of the Effect Derived from Silybin with Vitamin D and Vitamin E Administration on Clinical, Metabolic, Endothelial Dysfunction, Oxidative Stress Parameters, and Serological Worsening Markers in Nonalcoholic Fatty Liver Disease PatientsHCV point-of-care screening programme and treatment options for people who use drugs in a metropolitan area of Southern Italy
P50
Q31032339-7AABC9BC-28AC-4D4D-82FC-59C023511D1AQ33350030-2EAD5BBE-1A77-4993-B7A1-55A68BA55979Q33412844-24D25CC5-46C8-4B66-AB3D-47150E96E7B6Q33751826-20388871-B1FF-451D-9A46-3E8D064DB68EQ34467208-2221610E-BF91-4222-98CB-AF7A49EDBC6DQ34647400-433C0485-7D7B-40CE-866A-EBD8C2BD4742Q35044215-7CC2EEC7-ADEE-460C-9281-B842CCD594C7Q35095916-95DD848E-39AA-4591-8162-87A742CB6500Q35941510-59260F49-C2A1-4632-9948-7664A1A54F95Q36298719-3A51669C-6A09-41C3-8378-C3E88CE43C28Q37122348-A519F272-D9ED-4D7D-A727-C5FB02993ADAQ37879193-38B9170D-9B33-417D-AB31-BDE4E2D38251Q38629161-9DCD6DC6-A77B-49B8-873B-CA89AB7E61EAQ38676280-1EFC48FE-EB21-469A-8294-911B5E2FC9DEQ38681092-12E5EF3A-C642-4C15-9E85-CEB6BDA23627Q41487313-1AB02F4E-31F9-4A82-8781-D9BE7400ACD8Q41924669-23F32DFB-AF0A-44E8-B4D6-D9184196C560Q42538067-A1C23A7F-61A3-4606-A995-846CAAD1DA6FQ42980538-98B5F222-2F97-4F30-9BDA-D4B6CE699097Q43040750-C3C69484-5365-457A-9AD9-DC7DE55E7EDBQ44211166-E900490F-0542-4CA3-B427-3D0AD82FD5EFQ45257601-5E44D640-94D6-4A57-A934-BE7809C3B9C3Q45410983-EC2409C5-0FDD-4D05-9E11-E23688C67967Q46373769-D0FED47A-3568-4700-AAC2-C37E5E0DDF3CQ47152513-8EC1165F-4D17-407B-9A75-F67A0AF74160Q47177581-60E42243-5F22-408B-A49A-1FA7D5BE5A8AQ47720259-4C643739-3016-4172-82A2-8F18DEF670B6Q48264487-F4E6B22A-79E3-471A-B1C6-85B7CC6E675CQ50043358-4EFB3385-A818-4214-A8F2-FA0B13708160Q50266653-E34B5B84-3FC2-4CE1-8917-2AF867D47073Q51803900-23658CC5-89C1-4216-B755-71CA90254A92Q52674474-71A4A3FF-129C-4B26-916A-2F6A55C4CA3DQ55026430-54DDD8EE-7F56-4453-8942-6EC5E92861E9Q55501328-CD326610-9EBA-483C-9DF1-702C819F1055Q56958259-90CBF4DC-EDA3-47D1-858C-3055B0BAB799Q86082838-99A5C4E4-FAC3-4119-BC96-C630A6C317ECQ88493645-DA8302F3-AA93-4A74-94C1-9CB14FB34F85Q90654314-9A3A7528-03C7-4AA7-BCAF-4BF83E1D7803Q91317720-474EA155-089C-43F0-BFB8-F6AED5865ACBQ92560798-6EF78B77-A391-4D82-B1F4-8DE170EDC482
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
M Masarone
@ast
M Masarone
@en
M Masarone
@es
M Masarone
@nl
M Masarone
@sl
type
label
M Masarone
@ast
M Masarone
@en
M Masarone
@es
M Masarone
@nl
M Masarone
@sl
prefLabel
M Masarone
@ast
M Masarone
@en
M Masarone
@es
M Masarone
@nl
M Masarone
@sl
P106
P1153
24481941000
P31
P496
0000-0003-0550-8201